Search results

  1. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based..

    … Journal Leuk Lymphoma, 2024 …

  2. HDC.1 (LYHDC1)

    … with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Drug Name …

  3. Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.

    … Journal Clin Lymphoma Myeloma Leuk, 2025 …

  4. Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

    … Journal Clin Lymphoma Myeloma Leuk, 2025 …

  5. OZM-109 (LYTOZM109)

    … R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma Cancer …

  6. MSK 16-1536 (LYT209447)

    … and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma Cancer …

  7. LY.18 (LYLY18)

    … for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Cancer …

  8. (Acerta) ACE-LY-308

    … (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma Cancer …

  9. GO29781 (LYT29781)

    … Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia …

Back to top